Back
Sarepta Therapeutics Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Sell
36
SRPT
Sarepta Therapeutics
Last Price:
121.65
Seasonality Move:
7.54%
Sell
35
ALNY
Alnylam Pharmaceuticals
Last Price:
277.35
Seasonality Move:
10.72%
Sell
36
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $121.61. The Score for SRPT is 36, which is 28% below its historic median score of 50, and infers higher risk than normal.
- SRPT is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
35
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $277.43. The Score for ALNY is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.
- ALNY is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $121.61
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $277.43
The current trend is relatively stagnant and ALNY is experiencing buying pressure, which is a positive indicator for future bullish movement.
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.78 | Sell |
| Relative Strength Index (14 RSI): | 41.95 | Sell |
| Chaikin Money Flow: | 1293277 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (121.11 - 129.15) | Sell |
| Bollinger Bands (100): | (123.53 - 147.19) | Sell |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -1.2 | Sell |
| Relative Strength Index (14 RSI): | 49.43 | Sell |
| Chaikin Money Flow: | 435362 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (270.23 - 291.39) | Sell |
| Bollinger Bands (100): | (237.21 - 286.27) | Buy |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 124.38 | Sell |
| 20-day SMA: | 126.49 | Sell |
| 50-day SMA: | 126.18 | Sell |
| 200-day SMA: | 130.61 | Sell |
| 8-day EMA: | 124.31 | Sell |
| 20-day EMA: | 125.44 | Sell |
| 50-day EMA: | 127.48 | Sell |
| 200-day EMA: | 127.68 | Sell |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 272.5 | Buy |
| 20-day SMA: | 283.25 | Sell |
| 50-day SMA: | 273.97 | Buy |
| 200-day SMA: | 207.84 | Buy |
| 8-day EMA: | 274.92 | Buy |
| 20-day EMA: | 277.83 | Sell |
| 50-day EMA: | 272.73 | Buy |
| 200-day EMA: | 228.92 | Buy |
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.83 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.70 per share, and an increase next year of $8.80 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.86 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.48 per share, and an increase next year of $0.66 per share.
Sarepta Therapeutics Technical Analysis
| Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | Nov | |||||||||
| 28 | 29 | 30 | 31 | 01 | 04 | 05 | 06 | 07 | 08 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | Nov 4 | Nov 5 | Nov 6 | Nov 7 | Nov 8 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | Nov | |||||||||
| 28 | 29 | 30 | 31 | 01 | 04 | 05 | 06 | 07 | 08 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||